The KCNK2 antibody is a research tool designed to detect and study the KCNK2 protein, also known as TREK-1 (TWIK-related potassium channel 1). KCNK2 is a member of the two-pore domain potassium (K2P) channel family, which regulates cellular excitability and background potassium currents. It is widely expressed in the nervous system, heart, and other tissues, where it contributes to resting membrane potential maintenance, neurotransmitter release modulation, and responses to mechanical/chemical stimuli. Dysregulation of KCNK2 has been implicated in neurological disorders (e.g., depression, epilepsy), pain perception, and cardioprotective mechanisms. The KCNK2 antibody enables the investigation of its expression, localization, and functional roles through techniques like Western blotting, immunohistochemistry, and immunofluorescence. Researchers use it to explore KCNK2's involvement in physiological processes, such as neuroprotection against ischemia, and its potential as a therapeutic target. Recent studies also link KCNK2 to cancer progression and anesthetic responses, highlighting its biomedical relevance. Validation of antibody specificity (via knockout controls) is critical due to structural similarities among K2P channels. Commercial KCNK2 antibodies are typically developed in rabbit or mouse hosts, targeting specific epitopes within the protein's intracellular or extracellular domains.